6 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Showing 6 of 6 clinical reviews.
Resmetirom (Rezdiffra) lowers FibroScan liver stiffness and CAP scores in MASH patients. Review of MAESTRO-NASH data, monitoring timelines, and clinical interpretation of VCTE changes on therapy.
Resmetirom (Rezdiffra) lowers Free T4 through selective THR-β agonism. Learn the expected magnitude, time course, monitoring schedule, and when changes require clinical action.
Resmetirom (Rezdiffra) significantly lowers LDL cholesterol, triglycerides, apolipoprotein B, and lipoprotein(a) through selective thyroid hormone receptor beta activation in the liver. Review the MAESTRO-NASH lipid data, monitoring timelines, and clinical implications.
Resmetirom (Rezdiffra) is a selective thyroid hormone receptor beta agonist approved for MASH. Learn how it affects Free T3 levels, what the MAESTRO-NASH trial found, and when to monitor thyroid function.
What a GGT result can and cannot show during FDA-approved resmetirom treatment for eligible adults with noncirrhotic MASH and fibrosis.
Resmetirom (Rezdiffra) selectively activates thyroid hormone receptor beta in the liver, which can suppress TSH. Learn the mechanism, magnitude, monitoring schedule, and clinical management steps.